Vytrus Biotech S.A (VYT) | Stock Overview & Key Data
Vytrus Biotech S.A. | Small-cap | Healthcare
Vytrus Biotech S.A. | Small-cap | Healthcare
Vytrus Biotech S.A Performance Comparison
Stock Range
Today's Range
Low: €5.65
High: €5.75
on September 23, 2025
52 Week Range
Low: €2.10
High: €6.10
on November 5, 2024
on September 5, 2025
All-Time High: €6.10 on September 5, 2025
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Market Cap
€44.0M
EPS
0.14
P/E Ratio (TTM)
41.79
Forward P/E
17.98
P/B Ratio
6.04
PEG Ratio
N/A
Div. Yield
N/A
ROE
16.23%
Beta
0.026
Debt to Equity
24.31
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
15.45%
Profit Margin
16.76%
Returns and Earnings
Return on Assets (TTM)
6.02%
Return on Equity (TTM)
16.23%
EBITDA
€1.8M
Net Income (TTM)
€1.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.81
Quarterly Revenue Growth (YoY)
38.70%
Quarterly Earnings Growth (YoY)
174.30%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Vytrus Biotech S.A VYT | 44.02M Small-cap | -1.71% | -0.86% | 44.47% | 99.65% | 166.20% | 79.13% | 79.69% | 103.90% |
| Pharma Mar S.A PHM | 1.59B Large-cap | 4.44% | 8.43% | 13.02% | -0.39% | 11.68% | 82.08% | 64.46% | -19.75% |
| Oryzon Genomics S.A ORY | 217.81M Mid-cap | 31.39% | 30.43% | 36.36% | 18.03% | 140.00% | 94.59% | 71.43% | 24.14% |
| Biotechnology Assets BST | 25.64M Small-cap | -2.56% | -2.56% | 15.15% | 15.15% | 35.71% | 18.75% | 280.00% | -15.56% |
| Atrys Health S.A ATRY | 213.29M Mid-cap | -0.36% | -0.71% | 9.38% | -10.83% | -20.00% | -15.15% | -53.33% | -62.67% |
| Grifols, S.A GRF | 7.45B Large-cap | -0.83% | -3.95% | 17.57% | 29.60% | 25.90% | 17.34% | 34.12% | -52.40% |
Ownership & Short Interest
Insider Ownership
64.95%
Institutional Ownership
2.49%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
7K
Average 90-Day Volume
3K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is VYT's 52-week high and low?
- In the last 52 weeks, Vytrus Biotech S.A reached a high of €6.10 (on September 5, 2025) and a low of €2.10 (on November 5, 2024).
- What is the market cap and P/E ratio for VYT?
- Curious about Vytrus Biotech S.A's size and valuation? Its market capitalization stands at 44.02M. When it comes to valuation, the P/E ratio (trailing twelve months) is 41.79, and the forward P/E (looking ahead) is 17.98.
- Does VYT pay dividends? If so, what's the yield?
- As for dividends, Vytrus Biotech S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Vytrus Biotech S.A's main competitors or similar companies to consider before investing?
When looking at Vytrus Biotech S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Pharma Mar S.A
PHM1.59B Healthcare Biotechnology 82.08% 64.46% Oryzon Genomics S.A
ORY217.81M Healthcare Biotechnology 94.59% 71.43% Biotechnology Assets
BST25.64M Healthcare Biotechnology 18.75% 280.00% Atrys Health S.A
ATRY213.29M Healthcare Biotechnology -15.15% -53.33% Grifols, S.A
GRF7.45B Healthcare Drug Manufacturers - General 17.34% 34.12% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Vytrus Biotech S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Vytrus Biotech S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 16.23%, the Debt to Equity ratio from the most recent quarter is 24.31, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for VYT?
- Looking at Vytrus Biotech S.A's growth, its revenue over the trailing twelve months (TTM) was €6M. Compared to the same quarter last year (YoY), quarterly revenue grew by 38.70%, and quarterly earnings saw a YoY growth of 174.30%.
- How much of VYT stock is held by insiders and institutions?
- Wondering who owns Vytrus Biotech S.A stock? Company insiders (like executives and directors) hold about 64.95% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 2.49%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.